Suvorexant: A promising, novel treatment for insomnia

Joyce K. Lee-Iannotti, James M. Parish

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalNeuropsychiatric Disease and Treatment
Volume12
DOIs
StatePublished - Feb 25 2016

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
United States Food and Drug Administration
Therapeutics
Hypnotics and Sedatives
Maintenance
Safety
suvorexant

Keywords

  • Benzodiazepan receptor antagonist
  • CYP3A4
  • Insomnia
  • MK-4305
  • Orexin-receptor antagonist

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Suvorexant : A promising, novel treatment for insomnia. / Lee-Iannotti, Joyce K.; Parish, James M.

In: Neuropsychiatric Disease and Treatment, Vol. 12, 25.02.2016, p. 491-495.

Research output: Contribution to journalArticle

Lee-Iannotti, Joyce K. ; Parish, James M. / Suvorexant : A promising, novel treatment for insomnia. In: Neuropsychiatric Disease and Treatment. 2016 ; Vol. 12. pp. 491-495.
@article{21d6c8c0fb834a76b7819e0d50a5b204,
title = "Suvorexant: A promising, novel treatment for insomnia",
abstract = "Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.",
keywords = "Benzodiazepan receptor antagonist, CYP3A4, Insomnia, MK-4305, Orexin-receptor antagonist",
author = "Lee-Iannotti, {Joyce K.} and Parish, {James M.}",
year = "2016",
month = "2",
day = "25",
doi = "10.2147/NDT.S31495",
language = "English (US)",
volume = "12",
pages = "491--495",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Suvorexant

T2 - A promising, novel treatment for insomnia

AU - Lee-Iannotti, Joyce K.

AU - Parish, James M.

PY - 2016/2/25

Y1 - 2016/2/25

N2 - Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

AB - Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

KW - Benzodiazepan receptor antagonist

KW - CYP3A4

KW - Insomnia

KW - MK-4305

KW - Orexin-receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=84959449879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959449879&partnerID=8YFLogxK

U2 - 10.2147/NDT.S31495

DO - 10.2147/NDT.S31495

M3 - Article

AN - SCOPUS:84959449879

VL - 12

SP - 491

EP - 495

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -